#United States #Houston #Clinical Trials #Avance Biosciences #CLIA

Avance Biosciences Achieves CLIA Registration

Avance Biosciences, a prominent provider of analytical and bioanalytical services tailored for the pharmaceutical sector, has recently announced its successful registration with the Clinical Laboratory Improvement Amendments (CLIA). This significant milestone enables the company to provide high-complexity laboratory testing, reinforcing its capabilities in supporting clinical trials, regulatory submissions, and the development of companion diagnostics for biologic medications.

The achievement of CLIA certification is a testament to Avance Biosciences' commitment to quality and regulatory compliance. By adhering to stringent federal standards, the company ensures the reliability and reproducibility of vital clinical trial data. With CLIA registration, Avance is poised to offer a broad spectrum of specialized testing services, including biomarker validation, pharmacogenomics, and immunogenicity testing, which are crucial for the development of new therapeutics and diagnostic devices.

Enhancing Clinical Support and Drug Development

Xuening Huang, the CEO of Avance Biosciences, expressed that the CLIA registration represents a landmark advancement in the company's mission to bolster support for clinical trials and biopharmaceutical progress. Industry professionals reviewing their facilities noted that Avance has one of the most exemplary CLIA labs they have encountered, further highlighting their dedication to providing high-quality, compliant testing solutions.

The newly acquired capabilities under CLIA registration empower Avance to assist its clients in advancing a variety of drug types, including small molecule drugs and biologics. This portfolio encompasses innovative areas such as mRNA therapeutics, vaccines, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and gene and cell therapies. The rigorous adherence to CLIA standards not only facilitates accurate and consistent clinical data but also accelerates the journey toward regulatory approvals, ultimately resulting in timely access to innovative therapies for patients in need.

A Commitment to Innovation

Avance Biosciences specializes in GLP/GMP-compliant analytical services aimed at supporting the evolution of biological drugs and companion diagnostics. Their expertise extends to genomic, proteomic, immunoassay, and cell-based assay solutions, which are designed to meet specific regulatory requirements demanded by the pharmaceutical industry.

As a leading entity in its field, Avance is committed to fostering innovation and delivering results that drive the pharmaceutical industry forward. The CLIA registration not only underscores the company's operational excellence but also strengthens its role as a reliable partner for biopharmaceutical innovators.

For more information regarding Avance Biosciences and its newly CLIA-certified testing services, interested parties can visit their official website at www.avancebio.com.

In summary, Avance Biosciences' accomplishment in securing CLIA registration marks a pivotal moment in enhancing clinical trial support. With a focus on maintaining high standards and delivering precise testing solutions, the company is well-positioned to make a significant impact on the future of drug development and patient care in the biopharmaceutical landscape.